Intravenous immunoglobulins-understanding properties and mechanisms

Clinical and Experimental Immunology

Volumn 158, Issue SUPPL. 1, 2009, Pages 2-13

  Durandy, A ^a   Kaveri, S V ^b   Kuijpers, T W ^c   Basta, M ^d   Miescher, S ^e,f   Ravetch, J V ^g   Rieben, R ^h  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e BioVisions Inc   (United States)

^f ROCKEFELLER UNIVERSITY   (United States)

^g CSL Behring ^*

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

Complement; Dendritic cell; Fc receptor; Immunoglobulin; Sialylation

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BRAIN INFARCTION; CHILL; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DENDRITIC CELL; DERMATOMYOSITIS; DRUG BINDING; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; FEVER; GENETIC VARIABILITY; GUILLAIN BARRE SYNDROME; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE COMPLEX NEPHRITIS; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INTRACELLULAR SPACE; MACROPHAGE; MALAISE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; THROMBOCYTOPENIA; X LINKED AGAMMAGLOBULINEMIA;

ANIMALS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; INFLAMMATION; MICE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG;

EID: 72149111128     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04022.x     Document Type: Review

References (73)

1. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008 26 : 513 533.
2. Conley ME, Dobbs AK, Farmer DM et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009 27 : 199 227.
3. Durandy A, Wahn V, Petteway S, Gelfand EW. Immunoglobulin replacement therapy in primary antibody deficiency diseases - maximizing success. Int Arch Allergy Immunol 2005 136 : 217 229.
4. Gürcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007 41 : 812 823.
5. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 345 : 747 755.
6. Fanciulli M, Vyse TJ, Aitman TJ. Copy number variation of Fc gamma receptor genes and disease predisposition. Cytogenet Genome Res 2008 123 : 161 168.
7. Schaschl H, Aitman TJ, Vyse TJ. Copy number variation in the human genome and its implication in autoimmunity. Clin Exp Immunol 2009 156 : 12 6.
8. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003 101 : 758 765.
9. Bayry J, Lacroix-Desmazes S, Delignat S et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003 48 : 3497 3502.
10. Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res 2001 89 : 540 546.
11. Press R, Nennesmo I, Kouwenhoven M et al. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 2005 159 : 165 176.
12. Bayry J, Lacroix-Desmazes S, Kazatchkine MD et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 2004 104 : 2441 2443.
13. Scott-Taylor TH, Green MR, Eren E, Webster AD. Monocyte derived dendritic cell responses in common variable immunodeficiency. Clin Exp Immunol 2004 138 : 484 490.
14. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 2004 101 : 14210 14215.
15. Abe J, Jibiki T, Noma S et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005 174 : 5837 5845.
16. Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev 2000 14 : 14 30.
17. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982 306 : 1254 1258.
18. Kimberly RP, Salmon JE, Bussel JB et al. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984 132 : 745 750.
19. Brownlie RJ, Lawlor KE, Niederer HA et al. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med 2008 205 : 883 895.
20. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008 359 : 307 309.
21. Pottier L, Sapir T, Bendaoud B et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann NY Acad Sci 2007 1110 : 426 432.
22. Seite JF, Shoenfeld Y, Youinou P, Hillion S. What are the contents of the magic draft IVIg? Autoimmun Rev 2008 7 : 435 439.
23. de Grandmont MJ, Racine C, Roy A et al. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003 101 : 3065 3073.
24. Lemieux R, Bazin R, Néron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005 42 : 839 848.
25. Rigal D, Vermot-Desroches C, Heitz S et al. Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994 71 : 309 314.
26. Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008 111 : 715 722.
27. Kessel A, Ammuri H, Peri R et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007 179 : 5571 5575.
28. Tha-In T, Bayry J, Metselaar HJ et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008 29 : 608 615.
29. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol 2008 45 : 4073 4079.
30. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996 104 (Suppl 1 21 5.
31. Basta M, Langlois PF, Marques M et al. High-dose intravenous immunoglobulin modifies complement-mediated in-vivo clearance. Blood 1989 74 : 326 333.
32. Basta M, Fries LF, Frank MM. High dose of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991 77 : 376 380.
33. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989 84 : 1974 1978.
34. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994 94 : 1729 1735.
35. Basta M, Van Goor F, Luccioli S et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003 9 : 431 438.
36. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the control of complement action. Immunol Res 2000 22 : 137 146.
37. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996 156 : 749 757.
38. Rieben R, Roos A, Muizert Y et al. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in-vitro and in-vivo in a rat model of acute inflammation. Blood 1999 93 : 942 951.
39. Roos A, Rieben R, Faber-Krol MC, Daha MR. IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies. Xenotransplantation 2003 10 : 596 605.
40. Adams HP. Stroke: a vascular pathology with inadequate management. J Hypertens Suppl 2003 21 : S3 7.
41. D'Ambrosio AL, Pinsky DJ, Connolly ES. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 2001 7 : 367 382.
42. Arumugam TV, Tang SC, Lathia JD et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2007 104 : 14104 14109.
43. Gronski P, Bauer R, Bodenbender L et al. On the nature of IgG dimers. I. Dimers in human polyclonal IgG preparations: kinetic studies. Behring Inst Mitt 1988 82 : 127 143.
44. Gronski P, Bauer R, Bodenbender L et al. On the nature of IgG dimers. II. Idiotype-anti-idiotype complexes of polyclonal and monoclonal origin: size distribution patterns and molecular geometries. Dimers in human polyclonal IgG preparations: kinetic studies. Behring Inst Mitt 1988 82 : 144 153.
45. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990 144 : 1387 1395.
46. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994 139 : 159 172.
47. Vassilev TL. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995 8 : 405 413.
48. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci USA 1987 84 : 828 831.
49. Schaub A, Wymann S, Heller M et al. Self-reactivity in the dimeric intravenous immunoglobulin fraction. Ann NY Acad Sci 2007 1110 : 681 693.
50. Wymann S, Ghielmetti M, Schaub A et al. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens. Mol Immunol 2008 45 : 2621 2628.
51. VonGunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of IVIG. Autoimmun Rev 2008 7 : 453 456.
52. Spycher MO, Bolli R, Hodler G et al. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIG) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmun 1996 96 (Suppl. 1 96.
53. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 : 484 486.
54. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003 18 : 573 581.
55. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005 310 : 1510 1512.
56. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006 203 : 789 797.
57. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 313 : 670 673.
58. Anthony RM, Nimmerjahn F, Ashline DJ et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008 320 : 373 376.
59. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008 105 : 19571 19578.
60. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006 24 : 19 28.
61. Warmerdam PA, Nabben NM, van de Graaf SA et al. The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. J Biol Chem 1993 268 : 7346 7349.
62. Qiu WQ, de Bruin D, Brownstein BH et al. Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. Science 1990 248 : 732 735.
63. Gutierrez-Roelens I, Lauwerys BR. Genetic susceptibility to autoimmune disorders: clues from gene association and gene expression studies. Curr Mol Med 2008 8 : 551 561.
64. Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature 2006 444 : 444 454. (Pubitemid 44809057)
65. Koene HR, Kleijer M, Roos D et al. Fc gamma RIIIB gene duplication: evidence for presence and expression of three distinct Fc gamma RIIIB genes in NA(1+,2+)SH(+) individuals. Blood 1998 91 : 673 679.
66. De Haas M, Kleijer M, van Zwieten R et al. Neutrophil Fc gamma RIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 1995 86 : 2403 2413.
67. Huizinga TW, Kuijpers RW, Kleijer M et al. Maternal genomic neutrophil FcRIII deficiency leading to neonatal isoimmune neutropenia. Blood 1990 76 : 1927 1932.
68. Aitman TJ, Dong R, Vyse TJ et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006 439 : 851 855.
69. Willcocks LC, Lyons PA, Clatworthy MR et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008 205 : 1573 1582.
70. Fanciulli M, Norsworthy PJ, Petretto E et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007 39 : 721 723.
71. Schouten JP, McElgunn CJ, Waaijer R et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002 30 : e57.
72. Breunis WB, van Mirre E, Geissler J et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009 30 : E640 50.
73. Breunis WB, van Mirre E, Bruin M et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008 111 : 1029 1038.